Clinical trials: Sorafenib, completed
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving sorafenib together with docetaxel and cisplatin works in treating patients with metastatic or locally advanced gastric or gastroesophageal junction cancer that cannot be removed by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
- Trial name
- NCT00253370
- Testing
- BAY 43-9006, docetaxel, cisplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Liver Cancer
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01264705
- Testing
- bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Solid Tumors
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.
- Trial name
- NCT03477175
- Testing
- E7080, Comparator Drug, Comparator Drug: Sorafenib
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally…
- Conditions
- Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
- Trial name
- NCT00390325
- Testing
- Sorafenib Tosylate
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastroesophageal Junction Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to block certain proteins on the surface of some cancer cells called "growth factor receptors." Blocking these growth factor receptors can…
- Trial name
- NCT00917462
- Testing
- Sorafenib, administered orally, CT/MRI
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Renal Cell Carcinoma
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC.
- Trial name
- TIVO-1 (NCT01030783)
- Testing
- tivozanib (AV-951), Sorafenib
- Where
- 86 sites in United States, Argentina and 14 more
- Volunteers
- 517 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT00131937
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Neoplasms
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
- Trial name
- NCT00920816
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 125 sites in United States, Bosnia and Herzegovina and 12 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Background: Colorectal cancer (CRC) is a major public health problem in the U.S. and worldwide, and 5-year survival with widespread metastatic disease is less than 5%.
- Trial name
- NCT00326495
- Testing
- Cetuximab, BAY 43-9006
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Leukemia Cutis
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
- Trial name
- NCT01371981
- Testing
- Asparaginase, Bortezomib, Cytarabine
- Where
- 220 sites in United States, Australia and 3 more
- Volunteers
- 1,645 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Gastric Cancer
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor…
- Trial name
- NCT00565370
- Testing
- Capecitabine, Cisplatin, Sorafenib
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
This phase II trial is studying sorafenib tosylate and gene expression in patients undergoing surgery for high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00466752
- Testing
- sorafenib tosylate, microarray analysis, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Carcinoma, Renal Cell
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
The purpose of the study is to: Find out if patients receiving BAY43-9006 will live longer without tumor progression than those receiving standard therapy with interferon alpha-2a Find out if a higher dose of BAY43-9006 can…
- Trial name
- NCT00117637
- Testing
- Sorafenib (Nexavar, BAY43-9006), Interferon
- Where
- 42 sites in United States, France and 5 more
- Volunteers
- 189 people
- Sponsor
- Bayer
Stage IV Pancreatic Cancer
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
This randomized phase II is studying how well giving sorafenib with or without gemcitabine works in treating patients with metastatic pancreatic cancer.
- Trial name
- NCT00114244
- Testing
- sorafenib tosylate, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard…
- Trial name
- NCT00544167
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- SCRI Development Innovations, LLC
Carcinoma, Hepatocellular
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is Find out if patients receiving Sorafenib will live longer Find out if Sorafenib has any effect on patient reported outcomes Find out if Sorafenib prevents the growth or shrinks liver tumors and / or…
- Trial name
- NCT00492752
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 23 sites in China, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Bayer